Bris­tol-My­ers Squibb adds to its ros­ter of check­point com­bo stud­ies, part­ner­ing with Ar­ray and Ad­vax­is

The pa­rade of new im­muno-on­col­o­gy part­ner­ships con­tin­ued Tues­day morn­ing with two new al­liances on the check­point front from Bris­tol-My­ers Squibb $BMY.

Deal #1: Bris­tol-My­ers is step­ping in to work with Ar­ray Bio­Phar­ma on a new dou­ble- and triple-play com­bo for col­orec­tal can­cer. Ar­ray $AR­RY saw its shares surge 8% on the news it will be com­bin­ing its ex­per­i­men­tal MEK in­hibitor binime­tinib with Op­di­vo as well as Op­di­vo plus Yer­voy in a Phase I/II ex­plorato­ry study look­ing at cas­es of col­orec­tal can­cer with sta­ble mi­crosatel­lite tu­mors.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.